Rapamycin, also called sirolimus, is an mTOR inhibitor that extends lifespan in several animal models. In people, the evidence is much earlier: small trials of mTOR inhibition have measured immune-related outcomes, but no study has shown that rapamycin extends human lifespan. Longevity use is off-label and needs careful clinical review. 1 2
Not sure where to start? Take the 3-min clinical quiz.
See if you qualify →What is rapamycin, and why is it discussed for longevity?
Rapamycin is the common name for sirolimus, a medication that inhibits the mechanistic target of rapamycin, or mTOR. mTOR helps cells respond to nutrients, energy availability, and growth signals. Researchers study this pathway because its activity is linked to protein production, cell growth, and cellular cleanup processes such as autophagy. 1
Rapamycin vs sirolimus vs Rapamune
Rapamycin and sirolimus refer to the same active medication. Rapamune is a brand name for sirolimus. Everolimus, formerly called RAD001 in research, and temsirolimus are related mTOR inhibitors called rapalogs. They are not interchangeable in practice: each has its own approved uses, formulation, exposure pattern, and safety considerations. 1 4
How mTOR relates to aging biology
mTOR works in two major complexes, mTORC1 and mTORC2. Rapamycin most directly affects mTORC1, which is involved in growth and protein synthesis; longer or different exposure patterns may also affect mTORC2. This biology is one reason researchers are interested in rapamycin, but a pathway effect is not the same as a proven health or lifespan outcome in people. 1
Why animal results created interest
Animal and model-organism studies have repeatedly found lifespan or healthspan signals with rapamycin. That is a meaningful reason to run human research. Still, differences in metabolism, disease risk, drug exposure, and lifespan mean that animal findings cannot establish a human lifespan benefit. 1 6
Does rapamycin extend lifespan in humans?
No. As of 2026, no published human trial has shown that rapamycin extends lifespan. Human research is useful but limited, and it has not followed enough people for enough time to answer that question. 1 6
| Evidence type | What has been measured | What it can tell us | What it cannot tell us |
|---|---|---|---|
| Human randomized trial | Immune-related measures and influenza-vaccine response in older adults 2 | Whether mTOR inhibition can affect selected short-term immune outcomes | Whether rapamycin lengthens human life |
| Human disease trials | Disease outcomes and adverse events in cancer, vascular malformations, and inflammatory disease 4 5 7 | How mTOR inhibitors can work and cause harm in specific patient groups | The risk-benefit balance for healthy longevity use |
| Animal studies | Lifespan and healthspan-related outcomes 1 | Why mTOR is a plausible aging-research target | That people will have the same result |
| Cell research | Molecular pathways such as nutrient sensing and autophagy 1 | How a drug may affect cells | Real-world health, function, or lifespan in people |
What human studies have measured so far
In a randomized study of older adults, Mannick and colleagues examined low-dose mTOR inhibition and reported improved immune-function measures, including influenza-vaccine response. This was an important human proof-of-concept study, but it was not a lifespan trial and does not show that rapamycin slows aging across the body. 2
Why biomarkers are not the same as longer life
Immune-cell markers, vaccine responses, body composition measures, and other biomarkers can help researchers decide what to study next. They are not validated substitutes for living longer or avoiding disability. A treatment can change a biomarker without producing a lasting clinical benefit. 1 6
What registered trials can and cannot answer
The Participatory Evaluation of Aging with Rapamycin study is registered on ClinicalTrials.gov and reflects continued interest in testing rapamycin in aging research. A registered study is not evidence that a treatment works; results, peer review, and follow-up are needed before strong conclusions can be made. 8
What does animal and cell research suggest about rapamycin and aging?
Animal and cell studies suggest that mTOR inhibition can affect aging-related pathways, including nutrient sensing, protein handling, and autophagy. These findings are scientifically valuable, but they are early-stage evidence for patients, not proof that rapamycin will extend human life. 1
Lifespan and healthspan signals in model organisms
Across yeast, worms, flies, and rodents, rapamycin has been associated with longer lifespan in multiple studies reviewed in the longevity literature. Researchers also study function and disease-related outcomes in these models. The consistency makes mTOR a high-interest target, while the lack of definitive human outcomes remains the central evidence gap. 1
Autophagy and cellular maintenance
Autophagy is a process cells use to break down and recycle damaged components. mTOR signaling interacts with autophagy and other maintenance systems, including protein quality control. This is part of the broader biology discussed in our guide to cellular aging, but a cellular mechanism alone cannot prove a medication will improve human healthspan. 1
Why preclinical results may not translate
People do not live in controlled laboratory conditions. Genetics, diet, infections, other medications, baseline disease, and the timing of treatment can all change a drug's effects. For longevity medicine, the honest answer is that promising animal data justify better trials; they do not justify certainty. 1 6
What human clinical evidence exists for mTOR inhibition in older adults?
The clearest human aging-focused evidence is limited to selected outcomes, especially immune function, not lifespan. Studies of rapalogs in disease care add important safety information, but they should not be treated as longevity trials. 2 4
Immune-function findings from randomized trials
The 2014 randomized trial in older adults found that mTOR inhibition improved selected immune measures and influenza-vaccine response. It did not test whether participants lived longer, developed fewer age-related diseases overall, or maintained function for decades. 2
How rapalogs differ from rapamycin
Everolimus and temsirolimus are rapalogs, while sapanisertib is a different type of mTOR-pathway inhibitor studied in oncology. Their shared pathway does not mean they have the same effects, risks, or relevance to aging research. Drug-specific clinical evidence matters. 4 9
What disease-treatment trials can and cannot tell us
Everolimus has been tested in advanced pancreatic neuroendocrine tumors and hormone-receptor-positive breast cancer, while sirolimus has been studied for slow-flow vascular malformations. These trials show that mTOR inhibition can have condition-specific clinical effects and adverse events. They do not establish a favorable benefit-risk balance for healthy adults seeking longevity. 4 5 7
What are the downsides and side effects of rapamycin?
Rapamycin can have clinically important downsides. Mouth ulcers and infection-related concerns are among the risks discussed in the literature, alongside metabolic changes, delayed wound healing, reproductive concerns, and medication interactions. 3 6
| Potential consideration | Why it matters | What the evidence does and does not show |
|---|---|---|
| Mouth ulcers or mouth sores | They can be uncomfortable and may limit treatment tolerance 3 | Reported across mTOR-inhibitor use; frequency varies by medication, dose, schedule, and population |
| Infection concerns | mTOR inhibition can affect immune signaling 3 | Transplant and disease-treatment experience cannot be directly applied to intermittent longevity use |
| Metabolic effects | Glucose and lipid changes may matter for people with metabolic risk 3 | Long-term risk in otherwise healthy adults remains uncertain |
| Wound healing | mTOR signaling is involved in growth and repair 3 | Clinical context, surgery plans, and other conditions matter |
| Drug interactions | Sirolimus exposure can be altered by other medications 3 | A clinician and pharmacist need a full medication review |
Why transplant-dose data are not a direct match
Rapamycin has a long clinical history in transplant medicine, where immunosuppression is intentional and patients are monitored closely. Those regimens, patient populations, and treatment goals differ from proposed intermittent longevity use. Lower or less frequent exposure should not be assumed to be risk-free. 1 3
Why clinician oversight still matters
A licensed clinician can review medical history, current medicines, planned procedures, infection history, laboratory needs, and reasons to stop or pause treatment. For a deeper discussion of known risks, see our rapamycin side-effects guide. 3
How do people feel on rapamycin?
There is no reliable single answer. Individual experiences vary, and anecdotes about energy, illness, mood, or performance cannot show whether rapamycin caused a benefit or whether it is safe for a particular person. 1 6
Self-reported experiences can identify questions worth studying, but they are affected by expectations, other lifestyle changes, and who chooses to share their story. Symptoms such as persistent mouth sores, signs of infection, unusual bruising, severe gastrointestinal symptoms, or a concerning medication reaction should prompt medical review rather than online troubleshooting. 3
Is rapamycin a miracle drug for aging?
No. Rapamycin is a serious research candidate, not a proven anti-aging solution. Its animal evidence and mTOR biology are compelling, while the unanswered human questions about outcomes, safety, and patient selection are just as important. 1 6
A practical way to judge a longevity claim is to ask what kind of evidence supports it. Human randomized clinical outcomes deserve more weight than observational reports; observational findings deserve more weight than animal or cell results. Our longevity research guide explains why that evidence ladder matters when headlines move faster than clinical data. 6
Can you get rapamycin through Chia?
No. Chia does not currently offer rapamycin, sirolimus, Rapamune, everolimus, temsirolimus, or other rapalogs. We do not present rapamycin as a substitute for established preventive care or as a treatment for aging.
At Chia, our providers discuss the treatments we do offer only after an online clinical evaluation and only where clinically appropriate. If your goal is to understand aging biology, start with our evidence overview of rapamycin and bring focused questions to a licensed clinician who can review your full health picture.
What should patients ask before considering rapamycin for longevity?
The most useful conversation is not “Will this make me live longer?” It is “What is my individual benefit-risk case, given that lifespan benefit is unproven?” A licensed clinician should help assess whether there is a clear medical reason to consider an mTOR inhibitor at all. 1 3
- “Is there an approved or well-established medical indication relevant to me?” 1
- “Which current medicines, supplements, infections, surgeries, or health conditions could change the risk?” 3
- “What laboratory monitoring would be relevant, and what changes would lead us to reassess?” 3
- “What side effects should make me contact the care team or stop and seek urgent care?” 3
- “What outcome would count as meaningful benefit, given that human lifespan extension has not been established?” 6
Frequently asked questions about rapamycin and longevity
No. Rapamycin was first isolated from bacteria found on Rapa Nui, also known as Easter Island. Its current popularity comes from mTOR and animal-aging research, not from a proven population secret to slower aging. 3
References
- 1.Kaeberlein M, et al. Rapamycin for longevity: opinion article. Aging. 2019.
- 2.Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014.
- 3.Rapamycin for longevity: the pros, the cons, and future directions. Frontiers in Aging. 2025.
- 4.Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine. 2011.
- 5.Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine. 2012.
- 6.What is the clinical evidence to support off-label rapamycin for longevity? A review of current evidence. 2025.
- 7.Maruani A, Tavernier E, Boccara O, et al. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatology. 2021.
- 8.ClinicalTrials.gov. Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL), NCT04488601. 2026.
- 9.ClinicalTrials.gov. Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations, NCT03047213. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
Find what fits your body and your goals.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
